PT1343518E - Composições de interferão estabilizadas - Google Patents

Composições de interferão estabilizadas Download PDF

Info

Publication number
PT1343518E
PT1343518E PT01990949T PT01990949T PT1343518E PT 1343518 E PT1343518 E PT 1343518E PT 01990949 T PT01990949 T PT 01990949T PT 01990949 T PT01990949 T PT 01990949T PT 1343518 E PT1343518 E PT 1343518E
Authority
PT
Portugal
Prior art keywords
interferon compositions
stabilized interferon
stabilized
compositions
interferon
Prior art date
Application number
PT01990949T
Other languages
English (en)
Inventor
Sidney N Wolfe
Maninder S Hora
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of PT1343518E publication Critical patent/PT1343518E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
PT01990949T 2000-11-07 2001-11-07 Composições de interferão estabilizadas PT1343518E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24645600P 2000-11-07 2000-11-07
US25222400P 2000-11-21 2000-11-21

Publications (1)

Publication Number Publication Date
PT1343518E true PT1343518E (pt) 2009-08-03

Family

ID=26937990

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01990949T PT1343518E (pt) 2000-11-07 2001-11-07 Composições de interferão estabilizadas

Country Status (16)

Country Link
US (2) US6994847B2 (pt)
EP (1) EP1343518B1 (pt)
JP (2) JP4129178B2 (pt)
CN (1) CN1330372C (pt)
AU (2) AU3070702A (pt)
BG (1) BG66082B1 (pt)
CA (1) CA2428144C (pt)
CZ (1) CZ20031259A3 (pt)
DE (1) DE60139339D1 (pt)
ES (1) ES2330508T3 (pt)
HU (1) HU228583B1 (pt)
IL (2) IL155788A0 (pt)
NO (1) NO330690B1 (pt)
PL (1) PL209928B1 (pt)
PT (1) PT1343518E (pt)
WO (1) WO2002038170A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
AU2004260702A1 (en) * 2003-08-01 2005-02-10 Ability Biomedical Corporation Combination therapies for Multiple Sclerosis
US7276275B2 (en) * 2004-04-22 2007-10-02 Highland Industries, Inc. Laminated spacer fabric
WO2005108054A2 (en) * 2004-04-22 2005-11-17 Highland Industries, Inc. Spacer fabric
MX2007014148A (es) 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
BRPI0612752B8 (pt) * 2005-06-21 2021-05-25 Merck Patent Gmbh composição farmacêutica sólida compreendendo (r)-(-)-2-[5-(4-fluorfenil)-3-piridilmetilaminometil]cromano
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
CN101190329B (zh) * 2006-11-29 2013-03-06 信谊药厂 一种重组人p43蛋白的药物组合物及其在医药上的应用
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
JP5840148B2 (ja) * 2010-03-04 2016-01-06 フェニックス インク． 変性させることなく可溶性組換えインターフェロンタンパク質を産生する方法
CN102585011A (zh) * 2012-02-10 2012-07-18 中国农业大学 一种犬α干扰素衍生物的制备方法与应用
CN114569716A (zh) 2014-10-23 2022-06-03 美国安进公司 降低药物制剂的粘度
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US10799639B2 (en) * 2017-03-03 2020-10-13 Min Wei Syringe type medication delivery device
CN113797318B (zh) * 2021-10-26 2023-06-30 深圳科兴药业有限公司 一种干扰素组合物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439181A (en) 1981-01-26 1984-03-27 Regents Of The University Of Minnesota Polyol-hormone mixture for use in chronic parenteral hormone administration
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
EP0080879B1 (en) 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
AU1234383A (en) 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US5702699A (en) 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US5643566A (en) 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4462940A (en) 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
EP0133767B1 (en) 1983-08-04 1991-04-03 The Green Cross Corporation Gamma interferon composition
JPS6069037A (ja) 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
WO1985002118A1 (en) 1983-11-21 1985-05-23 Regents Of The University Of Minnesota A buffered polyol-hormone mixture for use in chronic parenteral hormone administration
US4605555A (en) 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US4808705A (en) * 1986-12-19 1989-02-28 Cetus Corporation Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor
US4894330A (en) * 1986-12-23 1990-01-16 Cetus Corporation Purification of recombinant beta-interferon incorporating RP-HPLC
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
IT1222427B (it) * 1987-07-31 1990-09-05 Sclavo Spa Procedimento per la purificazione di interferone
US5151265A (en) 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
IL89662A (en) * 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
ATE148165T1 (de) 1989-07-24 1997-02-15 Bayer Ag Stabilisierung von hochgereinigten proteinen
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
TW249202B (pt) 1993-08-13 1995-06-11 Ciba Gerigy Corp
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
FR2719479B1 (fr) 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5542303A (en) * 1994-05-12 1996-08-06 Neuffer; A. Erich Dual-peak torque measuring apparatus
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
AU696387B2 (en) * 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
EP0875253B1 (en) 1997-05-02 2005-04-06 Seikagaku Corporation Chondroitinase compositions
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta

Also Published As

Publication number Publication date
PL209928B1 (pl) 2011-11-30
JP4129178B2 (ja) 2008-08-06
HUP0301653A2 (en) 2007-02-28
US20060008447A1 (en) 2006-01-12
CZ20031259A3 (cs) 2004-01-14
NO20032033D0 (no) 2003-05-06
WO2002038170A3 (en) 2003-03-27
AU3070702A (en) 2002-05-21
AU2002230707B2 (en) 2006-08-24
US6994847B2 (en) 2006-02-07
HUP0301653A3 (en) 2009-03-30
US20020114782A1 (en) 2002-08-22
WO2002038170A2 (en) 2002-05-16
IL155788A (en) 2013-09-30
US7662369B2 (en) 2010-02-16
CA2428144A1 (en) 2002-05-16
ES2330508T3 (es) 2009-12-11
JP2004536021A (ja) 2004-12-02
CA2428144C (en) 2012-01-10
JP2008069171A (ja) 2008-03-27
BG66082B1 (bg) 2011-03-31
IL155788A0 (en) 2003-12-23
HU228583B1 (en) 2013-04-29
BG107887A (bg) 2004-01-30
EP1343518B1 (en) 2009-07-22
PL366329A1 (en) 2005-01-24
NO330690B1 (no) 2011-06-14
DE60139339D1 (de) 2009-09-03
CN1481252A (zh) 2004-03-10
EP1343518A2 (en) 2003-09-17
NO20032033L (no) 2003-07-03
CN1330372C (zh) 2007-08-08

Similar Documents

Publication Publication Date Title
IL153587A0 (en) Stabilized interleukin 2
EP1341554A4 (en) COMPOSITION IN COLOSTRUM BASIS
HUP0301653A2 (en) Stabilized interferon compositions
EP1320385A4 (en) COMBINATION COMPOSITIONS
GB0023891D0 (en) Composition
EP1270611A4 (en) COMPOSITION
GB0019651D0 (en) Compositions
GB2365006B (en) Refractory compositions
AU2001287852A8 (en) Composition
GB0004518D0 (en) Compositions
GB0007762D0 (en) Composition
GB0025058D0 (en) Composition
GB0031267D0 (en) Novel compositions
GB0004522D0 (en) Compositions
GB0018526D0 (en) Compositions
GB0013615D0 (en) Compositions
GB0001854D0 (en) Compositions
GB0017288D0 (en) Compositions
GB0014847D0 (en) Novel compositions
GB0000676D0 (en) Composition
GB0000845D0 (en) Composition
GB0001939D0 (en) Composition
GB0002115D0 (en) Composition
GB0000792D0 (en) Composition
GB0008118D0 (en) Composition